Abstract 16374: Prevelance and Characteristics of Atrial Fibrillation Among Heart Failure Patients in the Middle East Region: Insights From the Gulf aCute heArt failuRe rEgistry (Gulf CARE)
Background: Little is known about the epidemiology of atrial fibrillation (AF) among patients admitted with acute heart failure (HF) in the Middle East. Here, we describe the prevalence of AF and compare patient characteristics according to rhythm (AF versus sinus rhythm [SR]) in a large contemporary cohort of Middle Eastern patients admitted with acute HF.
Methods: We analyzed data from the Gulf acute HF registry, a prospective, multinational registry of patients admitted with the final diagnosis of acute HF in 47 hospitals in seven Middle Eastern Arab Gulf countries (recruited between February 13, 2012 and November 13, 2012).
Results: 5005 patients were admitted with acute HF. The prevalence of AF among HF patients was 16.7%. AF patients were more likely to be older (mean age 60.8 ±16 years vs. 59±15 years; P = 0.002). A higher percentage of female was present in the AF group compared to the SR group (45% vs. 36%; P = 0.001). Peripheral (PVD) and cerebral vascular disease (Stroke/TIA) were more common among patients with AF (6.1% vs. 4.2%; P = 0.02 and 15% vs. 6.7%; P = 0.001, respectively) while coronary artery disease was less common (41% vs. 48%; P = 0.001). Patients with AF were more likely to have a history of valvular heart disease (33.1% vs. 9.4%; P = 0.001), congenital heart disease (2.9% vs. 0.4%; P = 0.001), thyroid disease (7.1% vs. 2.8%; P = 0.001) and sleep apnoea requiring therapy (3.2% vs. 1.7%; P = 0.003)
Conclusion: AF is common among patients admitted with acute HF in the Middle East. Patients with AF tend to be older with more prevalent comorbidities including some potentially pre-disposing conditions. Improved management of these associated comorbidities may reduce the morbidity and mortality associated with HF and AF. Attention should be given to the presence of these conditions among patients with AF and HF for early recognition and management.
Author Disclosures: N.A. Asaad: None. K. Sulaiman: None. M. Mohsen: None. J. Al-Suwaidi: None. A. Alsheikh-Ali: Other Research Support; Modest; Medtronic, Behringer Ingelheim. Honoraria; Modest; Boehringer Ingelheim, Bayer, Pfizer. D. Darbar: None. R. Singh: None. P. Panduranga: None. H. AlFaleh: None. A. Elasfar: None. A. Al-Motarreb: None. W. Almahmeed: None. N. Bazargani: None. M. Ridha: None. B. Bulbanat: None. M. Al-Jarallah: None. H. Amin: None. K.F. AlHabib: None. C. Bollensdorff: None. A.M. Salam: None. M. Yacoub: None.
- © 2014 by American Heart Association, Inc.